Piramal Pharma Solutions Launches Advanced Facility in Michigan

Piramal Pharma Solutions (PPS) has unveiled a new, state-of-the-art payload-linker development suite at its Riverview, Michigan facility. This addition aims to bolster the company's capacity to support global payload-linker development and manufacturing, crucial for complex therapies like antibody-drug conjugates (ADCs).

This expansion is part of a broader $90 million investment to enhance PPS's U.S.-based manufacturing capabilities. Alongside this development, enhancements are planned for their sterile injectables facility in Lexington, Kentucky. Such strategic moves reflect PPS's commitment to swift and reliable delivery of innovative therapies.

Peter DeYoung, CEO of Piramal Global Pharma, highlighted the milestone, emphasizing the strengthened supply chain security and development acceleration for critical medicines. With over 60 years in drug substance development, the Riverview site is poised to meet the rising demand for ADCs.